Novocure

We strive to extend survival in some of the most aggressive forms of cancer. Patient images reflect patient(s) health status when photographed.

[Novocure @Novocure]

Novocure announced topline results today from the Phase 3 TRIDENT trial. Read more in our press release: https://t.co/9wvU07IjBf

[Novocure @Novocure]

Novocure today reported financial results for the first quarter that ended March 31, 2026. Read more in our press release: https://t.co/zYlrY8nOZu

[Novocure @Novocure]

Novocure will report financial results for the first quarter 2026 on April 30, 2026. Read more in our press release: https://t.co/aMMw0jIJIa

[Novocure @Novocure]

Novocure announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy. Read more in our press release: https://t.co/42QnnbK1lD

[Novocure @Novocure]

Today Novocure announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its treatment for non-small cell lung cancer through the country’s National Health Insurance coverage.

Read more in our press release: https://t.co/YEU1UsKDMn

[Novocure @Novocure]

Novocure today reported financial results for the quarter and full year ended December 31, 2025.

Read more in our press release: https://t.co/05fW4pfEFW

[Novocure @Novocure]

We are thrilled to see the news of our Optune Pax approval featured on the Nasdaq tower this morning.

Read more about the approval in our latest press release: https://t.co/bo8nPXIqm9

Thank you to the team at Nasdaq!

[Novocure @Novocure]

Yesterday, the U.S. Food and Drug Administration (FDA) approved Novocure’s treatment for adult patients with locally advanced pancreatic cancer concurrently with gemcitabine and nab-paclitaxel.

Read more in our press release: https://t.co/bo8nPXIqm9

[Novocure @Novocure]

The U.S. Food and Drug Administration (FDA) has approved Novocure’s treatment for adult patients with locally advanced pancreatic cancer concurrently with gemcitabine and nab-paclitaxel.

https://t.co/bo8nPXHSwB

[Novocure @Novocure]

Novocure today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Read more in our press release. https://t.co/4WtB45Zdx9

[Novocure @Novocure]

Novocure announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Read more in our press release: https://t.co/gJiky3RnX5

[Novocure @Novocure]

Novocure today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Read more in our press release: https://t.co/fjtyFjcxhY

[Novocure @Novocure]

Novocure announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Read more in our press release: https://t.co/8uIuzCTYD0

[Novocure @Novocure]

Novocure today reported financial results for the third quarter that ended September 30, 2025. Read more in our press release: https://t.co/7cOZzHnKly

[Novocure @Novocure]

Novocure to present data at the 2025 European Association of Neuro-Oncology (EANO) Meeting, held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, held October 17-21 in Berlin, Germany. https://t.co/vAluxJQEPy

[Novocure @Novocure]

Novocure will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Read more in our press release: https://t.co/919duCS4yw

[Novocure @Novocure]

Novocure's treatment for non-small cell lung cancer approved in Japan for concurrent use with PD-(L)1 inhibitors in unresectable advanced/recurrent NSCLC in patients who progressed on or after platinum-based chemotherapy: https://t.co/IDRebKrJ4w

[Novocure @Novocure]

Novocure today announced it submitted an application to the U.S. Food and Drug Administration (FDA) for the approval of Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. Read more: https://t.co/TDOvp6F2oE

[Novocure @Novocure]

Novocure today reported financial results for the second quarter ended June 30, 2025. Read the press release: https://t.co/32S9AWf8uL

[Novocure @Novocure]

Novocure will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for unresectable, locally advanced pancreatic cancer at the European Society for Medical Oncology (ESMO) GI Congress 2025. https://t.co/7wD96gAW88